CSF_PsA_Highlights_EULAR2022

EULAR 2022
Congress Preview
PsA
Steering Committee Introduction
Dear CSF Member,
Welcome to my selection of EULAR abstracts on PsA. In this brochure you’ll find 43 abstracts that I think you’ll find
particularly interesting. I have chosen 13 of those abstracts as my ‘Top Picks’ which, in my opinion, are not to be missed.
Among our choices from Day 1, we have an oral presentation by CSF Steering Committee chair, Professor Iain McInnes,
on clinical outcomes following upadacitinib treatment in the SELECT-PsA-1 and -2 clinical trials (OP0024). We also
have oral presentations on MACE with tofacitinib (OP0027) and improvement of fatigue in guselkumab Phase 3 trials
(OP0025). Our poster selections feature a range of topics, including efficacy of deucravacitinib (POS1039 and POS1048),
guselkumab (POS1037, POS1030 and POS1028), disease activity and patient-reported outcomes with ixekizumab
(POS0160) and for rizankizumab, we have posters on fatigue (POS1042) as well as a subgroup analysis of the KEEPsAKE
trials (POS1042).
Our poster selections continue into Day 2 with abstracts on efficacy (POS0072) and novel endpoints (POS0082) in
guselkumab trials, predicting better responses with deucravacitinib (POS0005) and effect of methotrexate on ustekinumab
treatment (POS0079).
The Emerging Treatment Strategies in PsA session on Day 3 caught our eye, and I’m sure it’ll catch yours too with
presentations on bimekizumab (OP0255), izokibep (OP0258) and guselkumab (OP0259). And on Day 4, we have the
Clinical Aspects in Psoriatic Arthritis poster session, which is not to be missed.
This year, we’re producing separate highlights brochures for PsA, RA and axSpA, so make sure to go to the Cytokine
Signalling Forum and download our other highlights brochures. If you’re looking for the latest on lupus, head over to
https://www.lupus-forum.com/ where you’ll find their EULAR selections.
All that remains is for me to thank you for your continued support, and to hope that – whether you’re joining in-person or
virtually – you have a great time at EULAR 2022!
Kind regards
Professor Peter Nash
SPONSORSHIP AND UNRESTRICTED EDUCATIONAL GRANTS FROM
Register for FREE content at www.cytokinesignalling.com
DEVELOPED UNDER
THE AUSPICES OF THE
Follow us at:
Cytokine Signalling Forum

Key Presentations
Wednesday, 01 June 2022
All day POSTER VIEW 7
POS0519
POS1015
POS1016
POS1017
POS1019
POS1022
POS1023
POS1024
POS1028
How does body mass index affect secukinumab
treatment outcomes and safety in patients with
psoriatic arthritis? – real world data from the German
AQUILA study
Uta Kiltz
Safety of guselkumab in patients with active psoriatic
arthritis who are bio-naïve or TNFi-experienced: pooled
results from 4 randomized clinical trials through
2 Years
Proton Rahman
Relationships between disease duration and
radiographic progression among patients with psoriatic
arthritis treated with secukinumab in FUTURE 5
Christopher T. Ritchlin
Guselkumab provides continued improvement in key
domains of psoriatic arthritis through 2 years
Laura Coates
Real-world evaluation of treatment patterns and
persistence of tofacitinib in treatment of psoriatic
arthritis in Australia: an analysis of the OPAL dataset
Geoff Littlejohn
Relationships between inhibition of radiographic
progression and achievement of low disease activity or
remission and their core components in patients with
psoriatic arthritis treated with secukinumab in FUTURE
5 during the first 24 weeks
Philip J Mease
Long-term safety of risankizumab in patients with
psoriatic disease: findings from integrated analyses of
17 clinical trials in psoriasis and 4 in psoriatic arthritis
Blair Kaplan
Efficacy and safety of risankizumab (RZB) for active
psoriatic arthritis (PsA): 52-week results from
KEEPsAKE 1
Lars Erik Kristensen
Guselkumab maintains resolution of dactylitis and
enthesitis in patients with active psoriatic arthritis:
results through 2 years from a phase 3 study
Proton Rahman
POS1029
POS1030
POS1031
POS1032
POS1035
POS1036
POS1037
POS1038
POS1039
Effects of treatment with risankizumab on minimal
disease activity (MDA) and disease activity in psoriatic
arthritis (DAPSA): an analysis of the KEEPsAKE-1 and
-2 Trials
Joseph F. Merola
Pain response in psoriatic arthritis patients treated
with guselkumab is driven predominantly by
inflammation-independent effects
Philip J Mease
Earlier clinical response predict low rates of
radiographic progression in bio-naive active psoriatic
arthritis patients receiving guselkumab treatment
Philip J Mease
Risankizumab for active psoriatic arthritis: integrated
subgroup analysis from 2 double-blind, placebocontrolled,
phase 3 studies (KEEPsAKE 1 and
KEEPsAKE 2)
Joseph F. Merola
Low rates of radiographic progression with 2 years of
guselkumab, a selective inhibitor of the interleukin-
23p19 subunit: results from a phase 3, randomized,
double-blind, placebo-controlled study of biologicnaïve
patients with active psoriatic arthritis
Philip J Mease
Efficacy and safety of risankizumab (RZB) for active
psoriatic arthritis (PsA): 52-week results from
KEEPsAKE 2
Andrew Ostor
Effect of guselkumab, a selective IL-23p19 inhibitor,
on axial-related endpoints in patients with active PsA:
results from a phase 3, randomized, double-blind,
placebo-controlled study through 2 years
Philip J Mease
Guselkumab efficacy in psoriatic arthritis assessed by
multi-domain composite indices: data from the Phase
3b COSMOS trial in a TNFi-IR population
Laure Gossec
Deucravacitinib, an oral, selective tyrosine kinase
2 inhibitor, in a phase 2 trial in psoriatic arthritis:
achievement of minimal disease activity and its
components
Arthur Kavanaugh

Chairman’s Picks
POS1040
POS1042
POS1043
POS1044
POS1048
POS1051
POS1053
POS1055
POS1060
Safety of deucravacitinib, an oral, selective tyrosine
kinase 2 inhibitor: as assessed by laboratory
parameters – results from a phase 2 trial in psoriatic
arthritis and 2 phase 3 trials in psoriasis
Roy M. Fleischmann
Impact of risankizumab on improving health-related
quality of life, work productivity, and reducing fatigue
among patients with active psoriatic arthritis: A pooled
analysis of two Phase 3 clinical trials
Lars Erik Kristensen
Strong correlation between short- vs long-form
composite measures of psoriatic arthritis disease
activity in a TNFi-IR population treated with
guselkumab: data from the Phase 3b COSMOS trial
William Tillett
Guselkumab provides consistent and durable pain
improvement in patients with active psoriatic arthritis:
results of 2 phase 3, randomized, controlled clinical
trials
Peter Nash
Safety and efficacy of deucravacitinib, an oral,
selective tyrosine kinase 2 inhibitor, in patients with
psoriatic arthritis: 52-week results from a randomised
phase 2 trial
Philip J Mease
To what extent are baseline characteristics in biologicexperienced
patients with psoriatic arthritis associated
with achievement of minimal disease activity at Week
24 of guselkumab treatment: A post hoc analysis of
the Phase IIIb COSMOS clinical trial
William Tillett
Long-term retention, effectiveness and safety
of secukinumab in patients with active psoriatic
arthritis or ankylosing spondylitis: Results from the
observational SERENA study
Uta Kiltz
Identification of PsA phenotypes with machine learning
analytics using data from a Phase 3 clinical trial
programme of guselkumab in a bio-naïve patient
population
Pascal Richette
Changes in disease activity and patient-reported
outcomes in psoriatic arthritis patients treated with
ixekizumab in a real-world US cohort
William Tillett
POS1065
POS1067
POS1070
16:30–
18:00
OP0024
OP0025
OP0027
Impact of hyperuricemia on clinical phenotype,
comorbidities, and response to secukinumab in
psoriatic arthritis: post hoc analysis of FUTURE and
MAXIMISE studies
Renaud Felten
Domains contributing to minimal disease activity
achievement in patients with psoriatic arthritis
receiving guselkumab
Laura Coates
Baseline determinants of pain response in patients
with psoriatic arthritis receiving guselkumab
Peter Nash
CLINICAL ASPECTS IN PSORIATIC
ARTHRITIS
Differentiation between IL-6 and IL-17 pathway
inhibition in relationship with clinical outcomes in
non-biological DMARD-IR and biological DMARD-IR
psoriatic arthritis patients treated with upadacitinib in
SELECT-PsA 1 and SELECT-PsA 2 studies
Iain McInnes
Factors associated with fatigue and its improvement –
a principal component analysis of patients with active
psoriatic arthritis from guselkumab phase 3 trials
Proton Rahman
Association between baseline cardiovascular risk
and incidence rates of major adverse cardiovascular
events and malignancies in patients with psoriatic
arthritis and psoriasis receiving tofacitinib
Lars Erik Kristensen

Chairman’s Picks
Thursday, 02 June 2022
12:00–
13:30
POS0072
POS0079
POS0082
12:00–
13:30
POS0005
POSTER TOUR AUDITORIUM 7:
NEW THERAPEUTIC AVENUES IN PSORIATIC
ARTHRITIS
Consistent long-term guselkumab efficacy across
psoriatic arthritis domains irrespective of baseline
patient characteristics
Iain McInnes
Does methotrexate impact ustekinumab
immunogenicity in patients with active psoriatic
arthritis? A post hoc analysis of samples from a
randomized, placebo-controlled trial
Sorwe Mojtahed Poor
A novel psoriatic arthritis composite endpoint
combining treatment targets for skin and joints:
pooled results from the guselkumab DISCOVER-1 and
DISCOVER-2 studies
Alexis Ogdie
POSTER TOUR AUDITORIUM 9:
CHALLENGES IN MEASURING AND
PREDICTING RMDs
Baseline biomarkers predict better responses to
deucravacitinib, an oral, selective tyrosine kinase 2
(TYK2) inhibitor, in a phase 2 trial in psoriatic arthritis
Christopher T. Ritchlin
Friday, 03 June 2022
10:30–
12:00
OP0255
OP0258
OP0259
10:30–
12:00
OP0294
EMERGING TREATMENT STRATEGIES
IN PSA
Bimekizumab in patients with active psoriatic arthritis
and an inadequate response to tumour necrosis
factor inhibitors: 16-week efficacy & safety from BE
COMPLETE, a phase 3, multicentre, randomised
placebo-controlled study
Joseph F. Merola
Izokibep (ABY-035) in patients with active psoriatic
arthritis – 16-week results from a phase 2 study
Frank Behrens
Minimal disease activity response patterns in bio-naïve
patients treated with guselkumab: a machine learning
analysis
Alen Zabotti
THE EARLY BIRD GETS THE WORM
Reduced joint synovitis assessment versus the Global
EULAR OMERACT Synovitis Score (GLOESS) to
predict the response to secukinumab in patients with
active psoriatic arthritis and inadequate response to
conventional disease-modifying anti-rheumatic drugs:
Exploratory results from the ULTIMATE trial
Maria-Antonietta D’Agostino
Saturday, 04 June 2022
10:15–
11:45
POS0308
POS0312
POSTER TOUR AUDITORIUM:
CLINICAL ASPECTS IN PSORIATIC ARTHRITIS
Effect of guselkumab on serum biomarkers in
psoriatic arthritis patients with inadequate response or
intolerance to tumor necrosis factor inhibitors:
results from the COSMOS study
Georg Schett
Real-world evidence on assessing psoriatic arthritis
by disease domain: an evaluation of the CorEvitas
psoriatic arthritis/spondyloarthritis registry
Philip J Mease
Register for FREE content at www.cytokinesignalling.com
DEVELOPED UNDER
THE AUSPICES OF THE
Follow us at:
Cytokine Signalling Forum